Considering the IPO within the last months, ACXP has proven to investor its ability to hold value although its SP is not trading alike. Do not be fooled by the numbers, the company has had prior success with EUA and applications via FDA. Though private during inception, the company seeks to fund its ongoing pipeline with diversity. Their current target product line is antibiotics, and have done well before its IPO. Considering the chart, with no prior data and just fundamentals, I have set the Gann Square and S Line to show its support and resistance. Currently trading on lower avg vol, good news could easily move SP. Good luck all.